巴瑞替尼在中重度 2019 冠状病毒病患者中的应用。
Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019.
机构信息
Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA.
Infectious Diseases, Atlanta Veterans Affairs Medical Center, Decatur, Georgia, USA.
出版信息
Clin Infect Dis. 2021 Apr 8;72(7):1247-1250. doi: 10.1093/cid/ciaa879.
Hyperinflammation is associated with increased mortality in coronavirus disease 2019 (COVID-19). In this retrospective, uncontrolled patient cohort with moderate -severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized, controlled clinical trials.
高炎症反应与 2019 冠状病毒病（COVID-19）患者的死亡率升高有关。在这项回顾性、非对照的中重度 COVID-19 患者队列研究中，巴瑞替尼联合羟氯喹治疗使 15 例患者中的 11 例康复。巴瑞替尼治疗 COVID-19 应在随机对照临床试验中进一步研究。
Zotero 插件